Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2024-05-03 00:00:00 ET · period of report 2024-05-02 · accession 0001787306-24-000070 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-03 | 2024-05-02 | ARQT | Watanabe Todd Franklin | See Remarks, Dir | S - Sale | $8.74 | -13.8K | 860.8K | -2% | -$120.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-02 | S | D | 13,783 | $8.74 | 860,750 | D | — | — | (F1) The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units. (F2) The transaction was executed in multiple trades in prices ranging from $8.47 to $9.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |